Recruiting

Assessment System

Sponsor:

M.D. Anderson Cancer Center

Code:

NCT00505245

Conditions

Caregiver

Health Care Provider

Malignant Neoplasm

Physician

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Accepted

Interventions

Interview

Quality-of-Life Assessment

Questionnaire Administration

Study Details

Brief summary:

This trial studies how well a new assessment system (MDASI or other MD Anderson-developed PRO instrument) works in measuring symptoms and the impact on quality of life in cancer patients. Development of a new assessment system may provide more information about the common symptoms that may occur in patients due to cancer and its treatment and how the symptoms impact quality of life.

Conditions

Caregiver

Health Care Provider

Malignant Neoplasm

Physician

Study ID

NCT00505245

Start date

Apr 13, 1999

Status verified date

Jul, 2026

Completion date

Apr 30, 2031

Anticipated

Primary completion date

Apr 30, 2031

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Accepted

Inclusion Criteria:

  • NORMAL SAMPLES: Community dwelling adults 18 years of age or older
  • PATIENT SAMPLES: Inpatients and outpatients 18 years of age or older, being followed at UT MD Anderson
  • EXPERT PANEL PROFESSIONAL PARTICIPANTS: Physician or other healthcare provider with at least 5 years of experience caring for patients with the disease and/or treatment of interest, at least one publication in the last 5 years dealing with the disease and/or treatment of interest (physician only), ability to speak and read English, consent to participate
  • EXPERT PANEL FAMILY CAREGIVERS PARTICIPANTS: Identification as a family caregiver by patient enrolled as expert panel participant with the disease and/or treatment of interest, 18 years of age or older, ability to speak and read English, consent to participate
  • EXPERT PANEL PATIENT PARTICIPANTS: Patient with identified family caregiver participating on Expert Panel, willingness to receive packet for expert panel participation

Exclusion Criteria:

  • EXPERT PANEL PATIENT PARTICIPANTS: Patient with identified family caregiver participating on expert panel, willingness to receive packet for expert panel participation

Study Design

Enrollment

6500 participants

Anticipated

Interventions and Outcome Measures

Arms

Observational (questionnaire, QOL assessment, interview)

Participants complete questionnaires and quality of life assessments, and may also complete interviews over 45 minutes periodically.

Interventions

Interview

Complete interview

Quality-of-Life Assessment

Complete quality of life assessment

Questionnaire Administration

Complete questionnaires

Primary outcome measure

  • MD Anderson Symptom Inventory (MDASI) tool or other MD Anderson-developed patient reported outcome (PRO) instrument validity [ Time Frame: Up to 21 years ]
  • MD Anderson Symptom Inventory (MDASI) tool or other MD Anderson-developed PRO instrument reliability. [ Time Frame: Up to 21 years ]
  • MD Anderson Symptom Inventory [ Time Frame: Baseline up to 21 years ]
  • Eastern Cooperative Oncology Group Functional Status scale [ Time Frame: Baseline up to 21 years ]
  • EuroQOL 5 Dimensions questionnaire [ Time Frame: Baseline up to 21 years ]
  • The change in the symptom severity and interference with the function [ Time Frame: Baseline up to 21 years ]
  • MD Anderson Symptom Inventory (MDASI) tool or other MD Anderson-developed PRO instrument sensitivity [ Time Frame: Up to 21 years ]
  • The quality of life questionnaire will be assessed. [ Time Frame: Up to 21 years ]

Central Contacts and Locations

Central contacts

Xin Shelley Wang

713-745-3504xswang@mdanderson.org

Locations

M D Anderson Cancer Center

Recruiting

Houston, Texas, United States, 77030

Contacts

Xin Shelley Wang

713-745-3504

Principal Investigator:

Xin Shelley Wang

More Information

Sponsor

M.D. Anderson Cancer Center

Last update posted

Jul 29, 2026

Last verified

Jul, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by M.D. Anderson Cancer Center on 2026-07-29.